Trials / Unknown
UnknownNCT03440060
Procalcitonin-guided Antibiotic Therapy During Severe Exacerbation of COPD
Procalcitonin-guided Antibiotic Therapy During Severe Exacerbation of COPD Requiring Mechanical Ventilation: a Controlled Randomized Trial
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- University Hospital, Mahdia · Academic / Other
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
This study assess whether a procalcitonin guided antibiotic therapy can reduce significantly unnecessary antibiotic prescription during severe exacerbation of COPD requiring mechanical ventilation without compromising patients' outcome. The first group of patients will receive systematically empiric antibiotic therapy and the second group will receive antibiotics only if procalcitonin value is at or greater than 0.25 ng/ml.
Detailed description
Recently, procalcitonin gained interest as the most reliable biomarker in predicting bacterial origin in low respiratory tract infections and sepsis. Procalcitonin was shown to be non-inferior to standard guidelines in guiding antibiotic therapy during COPD exacerbation, without worsening patients' outcomes, and with a significant reduction in antibiotic exposure. Its use to guide antibiotic treatment during COPD exacerbation may be more challenging because of the frequent colonization of the airways in patients with COPD, and thus it needs further evaluation. Additionally, until today, no interventional studies evaluating procalcitonin protocol have been conducted in ventilated COPD patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | procalcitonin | procalcitonin value will be obtained within 24 hours after ICU admission in both groups and will be taken into account in the procalcitonin group only |
Timeline
- Start date
- 2017-10-05
- Primary completion
- 2020-10-01
- Completion
- 2020-12-31
- First posted
- 2018-02-20
- Last updated
- 2019-05-13
Locations
1 site across 1 country: Tunisia
Source: ClinicalTrials.gov record NCT03440060. Inclusion in this directory is not an endorsement.